¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16
±³À°ÀÏÀÚ : 2024-03-16
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ)

±³À°ÁÖÁ¦ : 2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051  

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "»çÀüµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 30,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 40,000¿ø

ÇöÀåµî·Ï ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 40,000¿ø ºñȸ¿ø, ¿Â¶óÀΠȸ¿ø 50,000¿ø 

¿Â¶óÀÎ Âü¿© ¹«·á"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:10~10:30 Mechanisms of Metabolic Dysfunction and Disease Consequences of MASLD(NAFLD) ¼Õ¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:30~10:50 Impact of Metabolic Risk Factors on Prognosis in Patients with Chronic Viral Hepatitis À±ÀçÇö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 10:50~11:10 Guidance for Surveillance and Diagnosis of HCC in Patients with MASLD(NAFLD) °û±Ý¿¬(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:10~11:30 Recent Advances in Lean MASLD(NAFLD) and Sarcopenia À¯Á¤È¯(ÀÎÇÏÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 11:30~11:50 Discussion ( )

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 12:50~13:10 Lifestyle Modifications in Obese and Lean Patients with MASLD(NAFLD): Different Way? ±èÁÖ¿µ(¹ÙÀÌ¿À´ºÆ®¸®¿Â)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:10~13:30 Endocrinologic Practice for Diabetes, Osteoporosis, and Obesity in Chronic Liver Disease ±èÁøÈ­(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:30~13:50 Cardiovascular Practice for Dyslipidemia, Hypertension, and Atherosclerosis in Chronic Liver Disease Á¶°æÈÆ(Àü³²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 13:50~14:10 Specific Issues and Concerns in the Management of MASLD(NAFLD)-Related HCC Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:10~14:30 Discussion ( )

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 14:50~15:10 Introduction and Implications of New NAFLD Nomenclatures: MAFLD vs. MASLD À±¾ÆÀϸ°(ÇѾçÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:10~15:30 Noninvasive Evaluation of MASLD(NAFLD) and Liver Fibrosis: Clinically Applicable? ÀÌâÈÆ(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:30~15:50 Molecular Basis and Mechanisms of Progression of MASH(NASH) ÇÑ¿ëÇö(°­¿ø¾à´ë)

±³À°½Ã°£ 03¿ù 16ÀÏ ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ, ÄÁº¥¼ÇȦ (4Ãþ) 15:50~16:10 Current and Emerging Pharmacological Options for MASH(NASH) and Obesity À̽¿ø(°¡Å縯ÀÇ´ë)

Åä·Ð 03¿ù 16ÀÏ 16:10~16:30 Discussion ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦39ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium : 2024-03-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼øõÇâ´ëÇб³ºÎõº´¿ø NeuroAngio Hub °³¼Ò±â³ä ±¹Á¦½ÉÆ÷Áö¾ö : 2024-03-16
´ÙÀ½±Û Á¦22ȸ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-03-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21009 ºÎ»ê ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ºÎ»ê°æ³²Áöȸ Çмúȸ : 2024-06-25 0 4 2024-06-17
21008 °æ³² â¿ø½Ã ¼Ò¾Æû¼Ò³â°úÁöȸ ¿¬¼ö°­ÁÂ(¼Ò¾Æ ¼ÒÈ­±â Áúȯ) : 2024-06-25 0 4 2024-06-17
21007 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ Çмúȸ(±¸°­°ÇÁ¶Áõ) : 2024-06-25 0 4 2024-06-17
21006 ¼­¿ï (¿Â¶óÀÎ) 2024³â 6¿ù ¼Ò¾Æ½ÉÃÊÀ½ÆÄ Áý´ãȸ : 2024-06-24 0 3 2024-06-17
21005 °æ±â 2024³â ¼Ò¾Æ¼ö¸é¿¬±¸È¸ Á¦2Â÷ Áý´ãȸ(¿Â¶óÀÎ) : 2024-06-24 0 2 2024-06-17
21004 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú (¿Â¶óÀÎ) 29th Vestibular Function Test Workshop : 2024-06-23 0 2 2024-06-17
21003 ¼­¿ï ´ëÇѳëÀο©¼ºÀÇÇÐȸ Á¦33Â÷ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-06-23 0 1 2024-06-17
21002 ¼­¿ï ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦5ȸ ½ÉÈ­ ½ÉÆ÷Áö¾ö : 2024-06-23 0 2 2024-06-17
21001 ºÎ»ê ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Á¦19Â÷ Çмú´ëȸ : 2024-06-23 0 2 2024-06-17
21000 ¼­¿ï 2024³â 6¿ù ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 3 2024-06-17
20999 ¼­¿ï Á¦ 10ȸ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ¼­¿ïÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 1 2024-06-17
20998 ¼­¿ï ´ëÇѵÎÅëÇÐȸ 2024³â Ãá°èÇмú´ëȸ : 2024-06-23 0 1 2024-06-17
20997 ´ë±¸ 2024³â ´ëÇѼÒÈ­±âÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 2 2024-06-17
20996 °æ±â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °æÀÎÁöȸ Á¦7ȸ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-23 0 10 2024-06-16
20995 ¼­¿ï Á¦18ȸ ´ëÇѺñ°úÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-23 0 8 2024-06-16
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷